• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Scratching head. I have read the data - this is different from Adu how?

Quote
























anonymous said:
The benefit is questionable. The danger is real.
Click to expand...
711c3cd6-07c5-4949-bf0c-13fc1e23743e_text.gif
 




















You clearly didn’t read the studies because if you did you would be aware that there is a difference between the two drugs results. With Aduhelm one of the arms failed on efficacy. Lecanemab did not fail on efficacy. The benefit may be small but it is there. There are arguments to be made about the cost benefit of taking it but that doesn’t change the fact that there is a real measurable difference between the two drugs. Any statements to the contrary are either ill informed or disingenuous.
 




anonymous said:
You clearly didn’t read the studies because if you did you would be aware that there is a difference between the two drugs results. With Aduhelm one of the arms failed on efficacy. Lecanemab did not fail on efficacy. The benefit may be small but it is there. There are arguments to be made about the cost benefit of taking it but that doesn’t change the fact that there is a real measurable difference between the two drugs. Any statements to the contrary are either ill informed or disingenuous.
Click to expand...

The data is garbage for both products. That’s the point.
 




Top Bottom
Back
Quote